← The Wire·Regulation·

FDA asks Compass for survival trial before tovecimig cancer filing

The FDA recommended that Compass run a survival-benefit trial before seeking approval for tovecimig in previously treated, advanced biliary tract cancer. That feedback shifts the program toward a larger clinical and regulatory hurdle before a BLA can proceed.

The story

Compass Therapeutics said Sept. 22 that the FDA recommended a trial demonstrating a survival benefit for tovecimig in patients with previously treated, advanced biliary tract cancer. The recommendation came after FDA feedback and concerns the path to a Biologics License Application.

Compass is developing tovecimig for biliary tract cancer, a setting in which the company had been considering a BLA submission. The regulatory feedback changes that sequence by placing a survival-benefit trial ahead of the filing.

The decision directly affects Compass Therapeutics and its tovecimig program. The concrete mechanism is regulatory: a new trial would be required before the company could proceed with a BLA submission for this indication.

The announcement describes the FDA's recommendation rather than an approval decision, and the timing, design and outcome of any additional trial remain open. The next markers are Compass's plans for the study, any further FDA interactions and whether the company identifies a timetable for a potential BLA.

Our read · Tue, Sep 22

FDA recommended that Compass Therapeutics (CMPX) run a survival-benefit trial before filing tovecimig’s biliary cancer application.

Why. The added trial requirement lengthens the path to a BLA and introduces another efficacy hurdle before the program can advance toward approval. No dated next event is established, so the regulatory consequence is clear but does not support a forward directional call.

Both cases

The case it holdsThe program remains active, and a successful survival-benefit trial could preserve a future BLA path in previously treated, advanced biliary tract cancer.
The case it breaksThe FDA recommendation adds a required clinical hurdle before filing, leaving the timing and outcome of the approval path uncertain.

What could change this view: Compass could narrow or resolve the regulatory requirements through follow-up discussions with the FDA, or a future survival-benefit study could support the application.

CMPX stock page →
Your side is graded privately against closes after 10 trading days. Research, not advice.

Who reported it · 1

Keep reading

Latest on the Wire

Nvidia tumbles as US tech stocks enter bear market on AI spending fearsTrump threatens overseas AI data-centre ban for US firmsBitcoin drops below $59,000 as cash rush revives summer-low testGreer says US chip curbs will close China export-control loopholesBlackRock bitcoin ETF posts $541.1 million outflow as tech sell-off spreadsContinue on the Wire →

Top this week

Nvidia allies lobby board to bring back Jensen Huang as CEONvidia chair rules out Huang return as CEO after 75% sales outlookAnthropic Said to Guide IPO Pricing Above Market RangeNvidia interim CEO Colette Kress faces first earnings test after HuangAnthropic IPO could become the largest in US history on Thursday
The Wire at 7 AM ET, free. Top stories with a bull and a bear case on each, every morning. No account needed.

About this report

Reported by GlobeNewswire as Compass Therapeutics Provides Regulatory Update on Tovecimig in Biliary Tract Cancer Following FDA Feedback, . Who answers for this

The only report in this record. Closes are licensed end-of-day data from Databento; the move after a story is its first close against the close before it. How this is decided →

Kept as written · your side, if you take one, is graded privately against licensed closes after 10 trading days · nothing here is advice · How the Wire is made →